If you have landed on the recovery and immune collection, you are probably weighing one product, not building a four-part stack. The four here share a shelf and little else: two liposomal liquids (glutathione and vitamin C), a concentrated marine oil, and a gastrointestinal binder. Each sits on a different body of research, aimed at a different situation.
Here is what the studies actually measured for each, who they studied it in, and where the evidence stops.
Does oral glutathione raise your body's stores?
Glutathione is a tripeptide the body makes itself, central to how cells manage oxidative stress. For a supplement, the research question is narrower: can swallowing it raise what your body holds? The answer has shifted over the years.
An early 1992 study in seven healthy volunteers found a single 3 g oral dose produced no material rise in circulating glutathione, which was long read as evidence that oral glutathione went nowhere. Longer trials complicated that. A six-month randomised, placebo-controlled trial in 54 adults found 250 mg and 1,000 mg daily of standard oral glutathione raised levels across several body compartments, so duration and dose changed the picture the single-dose study painted.
Liposomal forms carry their own, thinner data. A 2018 study gave 12 adults 500 mg or 1,000 mg of a liposomal product daily for four weeks and reported increases from baseline in several glutathione measures, alongside some immune-cell markers. It ran without a placebo or a standard-glutathione comparison, used a different product, and tested more than the 325 mg in a serving of Liposomal Glutathione Complex. A 2026 crossover in 14 healthy adults compared micellar, liposomal and standard forms and found the format changed whole-blood exposure, though its endpoints were pharmacokinetic and it did not measure recovery or immune function.
So who is this for? The research speaks to people whose specific interest is raising measured glutathione stores, and it now suggests oral forms can do that given enough time. What none of these studies shows is that a higher reading changes how you recover or feel. This is a supplement with human data on blood levels and none on outcomes, and that gap is worth knowing before you buy.
Is liposomal vitamin C worth the premium over plain vitamin C?
Vitamin C absorption is self-limiting. In seven healthy volunteers, plasma concentrations plateaued as oral intake rose and the fraction absorbed dropped at higher doses, which is why doubling an oral dose does not double the blood level.
The most direct format comparison put the options side by side. Eleven adults took placebo, 4 g plain oral vitamin C, 4 g liposomal, and 4 g intravenous on separate occasions. The liposomal dose reached higher plasma concentrations than plain oral and lower than intravenous. The measured protection against an oxidative-stress challenge did not differ across the three active conditions.
That result sets a realistic expectation. Liposomal delivery can lift plasma vitamin C above what plain ascorbate reaches, but in the one trial that also measured a functional outcome, the extra plasma did not translate into more protection. The study used 4 g, four times the 1,000 mg in Liposomal Vitamin C.
Who does that suit? Someone who wants more circulating vitamin C from an oral dose than a standard tablet delivers, and who values the liquid format, has a preparation with human pharmacokinetic data behind it. Anyone counting on the higher blood level to do something specific is reaching past what the trial found.
Which situations were SPMs actually studied in?
Specialised pro-resolving mediators (SPMs) are lipid signals the body makes from omega-3 fatty acids during the resolution phase of inflammation. That mechanism is a genuine area of interest, and it is also where most of the evidence sits. The human studies split into two kinds.
Biomarker studies show an enriched oil does something measurable. A 2020 crossover in healthy volunteers found single doses raised circulating SPM concentrations and shifted some immune-cell markers in a dose- and time-dependent way. A 2022 study in 23 adults with obesity found four weeks of 2 g daily raised several SPMs, though immune-cell abundance did not move.
Outcome studies point at specific populations. A 2020 open-label study in adults with chronic pain reported changes in pain and quality-of-life scores over four weeks, but ran without a placebo group. A 2023 multicentre pilot randomised 85 adults with symptomatic knee osteoarthritis to an SPM-enriched oil or an olive-oil placebo; selected pain scores differed at weeks eight and twelve while functional scores did not. That trial was industry-funded and retrospectively registered, and described an enriched oil rather than the specific retail product.
So the outcome evidence for SPM Active, thin as it is, comes from clinical trial populations rather than from healthy people chasing general recovery. Even that evidence has limits worth weighing: the strongest study was industry-funded, registered after the fact, and tested an enriched oil rather than this specific product. For someone without a particular complaint, there is little in the research to go on. One practical note if you do take it: it is a concentrated fish oil, so count its EPA and DHA against any other omega-3 in your routine.
Should you take a binder?
Ultra Binder is the outlier, because the collection's research holds no study of what a binder is meant to do. It combines activated charcoal, chitosan, zeolite, modified citrus pectin and other materials marketed to bind compounds in the gut. The cited evidence speaks to one thing about that mix: activated charcoal's habit of soaking up more than intended.
In a randomised crossover, 25 g of activated charcoal given 30 minutes after diazepam, ibuprofen and citalopram reduced how much of each drug was absorbed. A separate study found a strong timing effect for the blood-pressure medicine amlodipine. Those were high-dose poisoning-model studies, far above the undisclosed charcoal content of a binder capsule, so they cannot quantify the interaction here. They do establish the direction: binders and oral medicines taken close together interact.
So who is a binder for? The cited research cannot say, because none of it tests the product; it speaks only to a practical constraint, which is that oral medications need spacing. Ultra Binder's label already directs four capsules well away from meals and medicines, and a pharmacist is the right person to ask about a specific drug. With no outcome evidence in hand, there is little basis to treat a binder as a recovery or immune product.
What actually helps, and when to ask
None of these four is a required stack, and none replaces the basics of recovery: sleep, food, and time. Sorted by what the research supports, they separate cleanly. Glutathione and liposomal vitamin C have human data on blood levels and little on outcomes, so they suit someone specifically interested in that biochemistry. SPM Active has its clearest evidence in people with joint pain, and a binder's cited evidence is about medicine timing rather than benefit.
If a recovery or immune concern is persistent, or you take prescription medication, a GP or pharmacist can weigh interactions, allergies and your own situation better than any label. The Recovery & Immune collection has all four in NZ stock once you have matched one to your question.
References
- Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. European Journal of Clinical Pharmacology, 1992;43:667-669. DOI: 10.1007/BF02284971 (PMID: 1362956)
- Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition, 2015;54:251-263. DOI: 10.1007/s00394-014-0706-z (PMID: 24791752)
- Sinha R, Sinha I, Calcagnotto A, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. European Journal of Clinical Nutrition, 2018;72:105-111. DOI: 10.1038/ejcn.2017.132 (PMID: 28853742)
- Solnier J, Du M, Zhang Y, et al. A targeted metabolomic assessment of oral glutathione bioavailability and safety in humans: a randomized crossover clinical trial. Antioxidants, 2026;15:354. DOI: 10.3390/antiox15030354
- Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proceedings of the National Academy of Sciences USA, 1996;93:3704-3709. DOI: 10.1073/pnas.93.8.3704 (PMID: 8623000)
- Davis JL, Paris HL, Beals JW, et al. Liposomal-encapsulated ascorbic acid: influence on vitamin C bioavailability and capacity to protect against ischemia-reperfusion injury. Nutrition and Metabolic Insights, 2016;9:25-30. DOI: 10.4137/NMI.S39764 (PMID: 27375360)
- Souza PR, Marques RM, Gomez EA, et al. Enriched marine oil supplements increase peripheral blood specialized pro-resolving mediator concentrations and reprogram host immune responses. Circulation Research, 2020;126:75-90. DOI: 10.1161/CIRCRESAHA.119.315506 (PMID: 31829100)
- Al-Shaer AE, Regan J, Buddenbaum N, et al. Enriched marine oil supplement increases specific plasma specialized pro-resolving mediators in adults with obesity. Journal of Nutrition, 2022;152:1783-1791. DOI: 10.1093/jn/nxac075 (PMID: 35349683)
- Callan N, Hanes D, Bradley R. Early evidence of efficacy for orally administered SPM-enriched marine lipid fraction on quality of life and pain in a sample of adults with chronic pain. Journal of Translational Medicine, 2020;18:401. DOI: 10.1186/s12967-020-02569-5 (PMID: 33087142)
- Möller I, Rodas G, Villalón JM, et al. Randomized, double-blind, placebo-controlled study of an SPM-enriched oil in symptomatic knee osteoarthritis: GAUDI study. Journal of Translational Medicine, 2023;21:423. DOI: 10.1186/s12967-023-04283-4
- Lapatto-Reiniluoto O, Kivistö KT, Neuvonen PJ. Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram. British Journal of Clinical Pharmacology, 1999;48:148-153. DOI: 10.1046/j.1365-2125.1999.00995.x (PMID: 10417490)
- Laine K, Kivistö KT, Laakso I, Neuvonen PJ. Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration. British Journal of Clinical Pharmacology, 1997;43:29-33. DOI: 10.1111/j.1365-2125.1997.tb00029.x (PMID: 9056049)
This article describes findings from published research for general educational purposes. It is not medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. If you take prescription medication or have a health condition, consult a qualified healthcare professional before adding a supplement.